Given patient convenience and compatibility with a range of formulations and doses, capsule based dry-powder inhalation (DPI) technology is becoming the preferred DPI drug delivery platform for respiratory and systemic applications.
List view / Grid view
Filter the results
Comparative human in-vivo study of an immediate release tablet over-encapsulated by gelatin and hydroxypropyl methyl cellulose capsules –impact of dissolution rate on bioequivalence.
Lonza Pharma&Biotech Launches Ibex™ Solutions – An Innovative New Concept in Biological Manufacturing and Development
Lonza’s commitment to constant innovation and adding value to its customers and partners is today demonstrated by the launch of Ibex™ Solutions – a unique addition to its current offering...
Lonza is hosting a free 60-minute webinar on 25 April 2017 on how to create a compelling business case for the implementation of a paperless QC testing solution.
Lonza will hold a free 60-minute webinar on 2 November 2016 titled “LIMS and MODA-EM™ Solution – A Comprehensive Solution for Pharmaceutical Manufacturing Quality Control.”
Working in stem cell research can be both immensely rewarding and notoriously challenging. One of the most prominent challenges is taking what are often exciting new advances in stem cell biology made in the research lab, and translating these into viable, impactful therapies for patients.
BioWa, Inc. and Lonza today announced that they have entered into research agreements with Pfizer Inc. allowing the use of the POTELLIGENT® CHOK1SV Cell Line in the research and development of multiple proprietary antibodies in Pfizer’s pipeline.
Lonza Walkersville, Inc. and Hyglos GmbH, a German biotech company, announced today that they have reached a mutually beneficial global settlement which includes a license agreement for Hyglos under certain Lonza patents in the area of endotoxin detection.
There are many Limulus Amebocyte Lysate (LAL) methods commercially available today. Hence, Lonza is hosting a free, 60-minute webinar entitled "Endotoxin Detection – Which Method Is Best for Me" at two different dates and times.
In November 2012, the US Food and Drug Administration accepted the use of the MycoTOOL® PCR Mycoplasma Detection Kit as a release method for a biopharmaceutical product manufactured by Roche Applied Science intended for distribution in the United States.
Lonza, a leader in biological development and BaroFold, Inc., an innovative protein technology developer, announced today a non-exclusive technology and license agreement whereby Lonza will evaluate BaroFold’s PreEMT™ high pressure refolding technology for use in biological development refolding processes.
Lonza to expand Antibody Drug Conjugate (ADC) manufacturing capacity to meet growing customer demand
Lonza today announced plans to invest CHF 14 million to expand Antibody Drug Conjugate (ADC) manufacturing capacity in Visp, Switzerland. Oncology therapeutics including ADCs represent one of the fastest growing segments of the pharma and biotech industry and the deployment of ADC targeted therapies has intensified in recent years.
Lonza and OncoMed Pharmaceuticals sign a process development and manufacturing collaboration and multi-product GS license agreement
Lonza, a global leader in biological manufacturing and OncoMed Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to improving cancer treatment, announced today an agreement for the development and manufacture of OncoMed’s pipeline of anti-cancer stem cell therapeutics.
The National Institutes of Health Center for Regenerative Medicine (NIH CRM) has awarded Lonza Walkersville, Inc. a contract to generate induced pluripotent stem cells (iPSCs) under current Good Manufacturing Practices (cGMP). The production of clinical grade iPSCs is considered a critical component to realizing the therapeutic potential of pluripotent stem…